Skip Navigation



ToxSci Advance Access published online on March 15, 2007
Toxicological Sciences, doi:10.1093/toxsci/kfm056
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
98/1/39    most recent
kfm056v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lorge, E.
Right arrow Articles by Claude, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lorge, E.
Right arrow Articles by Claude, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

A Strategy in Genotoxicity Testing in Drug Development: Some Examples

Elisabeth Lorge*,1, Véronique Gervais*, Nathalie Becourt-Lhote*, Catherine Maisonneuve*, Jean-Luc Delongeas* and Nancy ClaudeH

* Servier Group, Drug Safety Assessment, 45403 Orléans-Gidy, France H Servier Group, Institut de Recherches Internationales Servier, 92400 Courbevoie, France

1 Biologie Servier BP 43255, 45403 Fleury-les-Aubrais, France; elisabeth.lorge{at}fr.netgrs.com; Fax: +33 2 38 23 86 50.

Received January 25, 2007; revision received March 7, 2007; accepted March 7, 2007


  Abstract

The minimal 3-test battery of the ICH guideline has been in use since 1997 for the development of new pharmaceuticals (ICH, 1997). After a 10-year experience of this core battery in regulatory genotoxicity testing, everywhere the time has come for reflection about what was learned from this experience. Different aspects of genotoxicity testing are currently being debated under different organizations (IWGT, 2007; Kirkland et al., 2007; HESI, 2006). The main concerns are to develop relevant strategies and adequate complementary tests to the minimal battery, appropriate for each specific case to assess risk for humans when in vitro positive results or findings in rodent bioassays for carcinogenicity are found. In this paper, an example of an in-house decision-tree is shown, with some options which can contribute to the current reflections. Additionally, tools built for early genotoxicity are presented.

Key Words: Drug Safety; Genotoxicity Strategy; Genotoxicity Battery.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.